[1] Ludwig J, Viggiano T R, Mcgill D B, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980, 55(7): 434-438.
[2] Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67(1): 328-357.
[3] Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1): 202- 209.
[4] Rinella M E, Lazarus J V, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023,
[5] Eslam M, Sanyal A J, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158(7): 1999-2014 e1.
[6] Lim G E H, Tang A, Ng C H, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol, 2023, 21(3): 619-29 e7.
[7] Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther, 2021, 54(9): 1100-1109.
[8] Kim D, Konyn P, Sandhu K K, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol, 2021, 75(6): 1284-1291.
[9] Nguyen V H, Le M H, Cheung R C, et al. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol, 2021, 19(10): 2172-2181 e6.
[10] Wen W, Li H, Wang C, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne), 2022, 13(934225.
[11] Wang X, Wu S, Yuan X, et al. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. J Clin Endocrinol Metab, 2022, 107(2): e745-e55.
[12] Lee H, Lee Y H, Kim S U, et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol, 2021, 19(10): 2138-2147 e10.
[13] Taylor R S, Taylor R J, Bayliss S, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158(6): 1611-1625 e12.
[14] Zheng K I, Sun D Q, Jin Y, et al. Clinical utility of the MAFLD definition. J Hepatol, 2021, 74(4): 989-991.
[15] Xing Y, Fan J, Wang H J, et al. Comparison of MAFLD and NAFLD Characteristics in Children. Children (Basel), 2023, 10(3):560.
[16] Anderson E L, Howe L D, Jones H E, et al. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One, 2015, 10(10): e0140908.
[17] Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition?. J Hepatol, 2023,
[18] De A, Bhagat N, Mehta M, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol, 2023,
[19] Ratziu V, Boursier J;AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol, 2023,
[20] Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol, 2023, |
